Title:
RECOMBINANT MEASLES VIRUS USEFUL AS BIVALENT VACCINE AGAINST MEASLES AND MALARIA INFECTION
Document Type and Number:
WIPO Patent Application WO/2011/061848
Kind Code:
A1
Abstract:
Disclosed is a vaccine which is safe and effective on malaria infection. Also disclosed is a vector for use in the production of the vaccine. Further disclosed is a bivalent vaccine which has an excellent protective effect on a measles virus and malaria infection and is free of complications upon inoculation. Specifically disclosed is a recombinant measles virus produced by inserting a gene encoding a protein involved in the protection against onset of malaria infection into a measles virus genome. The protein involved in the protection against onset of malaria infection is preferably selected from pfEMP-1, MAEBL, AMA-1, MSP-1, LSA-1, Pfs230 and others. Also specifically disclosed are a bivalent vaccine against measles and malaria infection, which comprises the recombinant measles virus. Further specifically disclosed is an anti-serum produced from a body fluid collected from an animal infected by the recombinant measles virus. Still further specifically disclosed is a method for producing a vaccine against malaria infection, which is characterized by using a measles virus as a vaccine vector.
Inventors:
KAI CHIEKO (JP)
YONEDA MISAKO (JP)
YONEDA MISAKO (JP)
Application Number:
PCT/JP2009/069691
Publication Date:
May 26, 2011
Filing Date:
November 20, 2009
Export Citation:
Assignee:
ARIGEN PHARMACEUTICALS INC (JP)
KAI CHIEKO (JP)
YONEDA MISAKO (JP)
KAI CHIEKO (JP)
YONEDA MISAKO (JP)
International Classes:
C12N7/00; A61K35/76; A61K39/015; A61K39/395; A61P31/14; A61P33/06; C12N15/09; A61K39/00
Other References:
LI, S. ET AL.: "Viral vectors for malaria vaccine development.", VACCINE, vol. 25, 2007, pages 2567 - 2574, XP005925103
TANGY, F. ET AL.: "Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector.", VIRAL IMMUNOL., vol. 18, no. 2, 2005, pages 317 - 326, XP008088160
GAMAIN, B. ET AL.: "The surface variant antigens of Plasmodium falciparum contain cross-reactive epitopes.", PROC NATL ACAD SCI U S A., vol. 98, 2001, pages 2664 - 2669
See also references of EP 2511367A4
TANGY, F. ET AL.: "Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector.", VIRAL IMMUNOL., vol. 18, no. 2, 2005, pages 317 - 326, XP008088160
GAMAIN, B. ET AL.: "The surface variant antigens of Plasmodium falciparum contain cross-reactive epitopes.", PROC NATL ACAD SCI U S A., vol. 98, 2001, pages 2664 - 2669
See also references of EP 2511367A4
Attorney, Agent or Firm:
HIROSE SHOICHI (JP)
Hirose Shoichi (JP)
Hirose Shoichi (JP)
Download PDF: